Literature DB >> 11258677

Kallikrein and kinin receptor expression in inflammation and cancer.

K Bhoola1, R Ramsaroop, J Plendl, B Cassim, Z Dlamini, S Naicker.   

Abstract

The kallikrein family of serine proteases has been investigated in many inflammatory disorders as molecular mapping, gene characterisation and cloning of kinin receptor genes have unfolded experimentally. In the molecular events of the inflammatory response the kallikrein cascade plays a significant role, since it is considered to initiate and maintain systemic inflammatory responses and immune-modulated disorders. A primary event is the chemotactic attraction of neutrophils which deliver the kallikrein-kinin cascade to sites of cellular injury and carcinogenic transformation of cells. The present study establishes the casual involvement of the kallikrein cascade in infection, inflammatory joint disease, acute transplant rejection, renal glomerular diseases, angiogenesis and carcinoma. We provide strong evidence for new or enhanced expression of kinin B1 receptors in inflammation, and additionally the induction of kallikrein genes in angiogenesis and carcinoma. The results provide insights into possible roles of kallikrein inhibitors and kinin receptor antagonists.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11258677     DOI: 10.1515/BC.2001.013

Source DB:  PubMed          Journal:  Biol Chem        ISSN: 1431-6730            Impact factor:   3.915


  18 in total

Review 1.  Role of G protein-coupled receptors in inflammation.

Authors:  Lei Sun; Richard D Ye
Journal:  Acta Pharmacol Sin       Date:  2012-02-27       Impact factor: 6.150

2.  Differential expression of multiple kallikreins in a viral model of multiple sclerosis points to unique roles in the innate and adaptive immune response.

Authors:  Michael Panos; George P Christophi; Moses Rodriguez; Isobel A Scarisbrick
Journal:  Biol Chem       Date:  2014-09       Impact factor: 3.915

Review 3.  Kinin B1 receptors: key G-protein-coupled receptors and their role in inflammatory and painful processes.

Authors:  João B Calixto; Rodrigo Medeiros; Elizabeth S Fernandes; Juliano Ferreira; Daniela A Cabrini; Maria M Campos
Journal:  Br J Pharmacol       Date:  2004-11-01       Impact factor: 8.739

4.  Critical role for PAR1 in kallikrein 6-mediated oligodendrogliopathy.

Authors:  Joshua E Burda; Maja Radulovic; Hyesook Yoon; Isobel A Scarisbrick
Journal:  Glia       Date:  2013-07-08       Impact factor: 7.452

5.  Passive targeting of nanoparticles to cancer: A comprehensive review of the literature.

Authors:  Remon Bazak; Mohamad Houri; Samar El Achy; Wael Hussein; Tamer Refaat
Journal:  Mol Clin Oncol       Date:  2014-07-23

6.  Upregulation of tissue kallikrein, kinin B1 receptor, and kinin B2 receptor in mast and giant cells infiltrating oesophageal squamous cell carcinoma.

Authors:  Z Dlamini; K D Bhoola
Journal:  J Clin Pathol       Date:  2005-09       Impact factor: 3.411

7.  Functional and molecular characterization of kinin B1 and B 2 receptors in human bladder cancer: implication of the PI3Kγ pathway.

Authors:  V Sgnaolin; T C B Pereira; M R Bogo; R Zanin; A M O Battastini; F B Morrone; M M Campos
Journal:  Invest New Drugs       Date:  2012-12-07       Impact factor: 3.850

8.  Kallikreins are associated with secondary progressive multiple sclerosis and promote neurodegeneration.

Authors:  Isobel A Scarisbrick; Rachel Linbo; Alexander G Vandell; Mark Keegan; Sachiko I Blaber; Michael Blaber; Diane Sneve; Claudia F Lucchinetti; Moses Rodriguez; Eleftherios P Diamandis
Journal:  Biol Chem       Date:  2008-06       Impact factor: 3.915

9.  Kallikreins and lupus nephritis.

Authors:  Claudio Ponticelli; Pier Luigi Meroni
Journal:  J Clin Invest       Date:  2009-04       Impact factor: 14.808

10.  LF 16-0687 Ms, a bradykinin B2 receptor antagonist, reduces ischemic brain injury in a murine model of transient focal cerebral ischemia.

Authors:  Li Ding-Zhou; Isabelle Margaill; Bruno Palmier; Didier Pruneau; Michel Plotkine; Catherine Marchand-Verrecchia
Journal:  Br J Pharmacol       Date:  2003-08       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.